# Bristol-Myers Squibb Company (BMY) — Q2-2018 Earnings Results

**Report date:** 2018-07-26 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q2-2018

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Down 1.9%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.01 | N/A | +13.95% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of optimism regarding their drug portfolio. However, they did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management highlighted the strong performance in their key drug segments.

> They expressed confidence in ongoing clinical trials and pipeline developments.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report shows a solid EPS beat, which indicates strong underlying performance. However, the stock declined by 1.9%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more comprehensive information on the company's future prospects.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q2-2018_